CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Project Agreement • November 3rd, 2022 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 03 hereby amends Project Agreement No. 01 as follows:
June 23, 2021Project Agreement • November 3rd, 2022 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference: MCDC Base Agreement No. 2020-504 Dear :McDc Base Agreement • November 3rd, 2022 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 02 hereby amends the Base Agreement as follows:
